Klinicheskaya effektivnost'i bezopasnost' primeneniya otechestvennogo rekombinantnogo granulotsitarnogo koloniestimuliruyushchego faktora Neypomaks® u bol'nykh rakom molochnoy zhelezy, poluchayushchikh khimioterapiyu doksorubitsinom i dotsetakselom
- Authors: Zhukova LG1, Abramov ME1, Vakhabova Y.V1, Lud AN1, Obukhov AA1, Lichinitser MR1
-
Affiliations:
- ГУ РОНЦ им. Н.Н.Блохина РАМН, Москва
- Issue: Vol 11, No 3 (2009)
- Pages: 50-54
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26785
- ID: 26785
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
L G Zhukova
ГУ РОНЦ им. Н.Н.Блохина РАМН, Москва
M E Abramov
ГУ РОНЦ им. Н.Н.Блохина РАМН, Москва
Yu V Vakhabova
ГУ РОНЦ им. Н.Н.Блохина РАМН, Москва
A N Lud
ГУ РОНЦ им. Н.Н.Блохина РАМН, Москва
A A Obukhov
ГУ РОНЦ им. Н.Н.Блохина РАМН, Москва
M R Lichinitser
ГУ РОНЦ им. Н.Н.Блохина РАМН, Москва
References
- Misset J.L., Dieras V, Gruia G et al. Dosefinding study of docetaxel and doxorubicin in first - line treatment of patients with metastatic breast cancer. Ann Oncol 1999; 10: 553–60.
- Aihara T, Takatsuka Y, Itoh K et al. Phase II study of concurrent administration of doxorubicin and docetaxel as first - line chemotherapy for metastatic breast cancer. Oncology 2003; 64: 124–30.
- Chirivella I, Bermejo B, Insa A et al. Impact of chemotherapy dose - related factors on survival in breast cancer patients treated with adjuvant anthracycline - based chemotherapy. ASCO Meeting Abstracts, Jun 2006; 24: 668.
- Nabholtz J.M. et al. Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First - Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial. J Clin Oncol 2003; 21: 968–75.
- Smith T.J. et al. Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence - Based Clinical Practice Guideline J Clin Oncol 2006; 24: 3187–205.
- Aapro M.S. et al. EORTC guidelines for the use of granulocyte - colony stimulating factor to reduce the incidence of chemotherapy - induced febrile neutropenia in adult patients with lymphomas and solid tumors. Eur J Cancer 2006; 42: 2433–53.
- Hoge H et al. Clinical Toxicology of Commercial Products. Acute poisoning. Ed. IV, Baltimore, 1975; p. 427.